TheraRadar
Landscape → Oncology

Prostate Cancer Clinical Trial Landscape

Data updated: May 20, 2026

2,260 clinical trials tracked since 2008

Prostate cancer is a disease in which malignant cells form in the tissues of the prostate, a gland in the male reproductive system. Clinical trials are essential for developing new and improved treatments for this condition. Since 2008, 2,244 prostate cancer trials have been registered, with 863 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 2, with 541 trials, followed by Phase 1 with 298 trials. Phase 3 trials account for 154 active trials, while Phase 4 trials represent 24 active trials. Industry sponsorship is led by Novartis, which currently has 22 active trials. AstraZeneca follows with 17 active trials, and Jiangsu HengRui Medicine Co., Ltd. has 11. Pfizer and Bayer are also notable sponsors, with 8 and 7 active trials, respectively. The high volume of Phase 2 trials suggests a strong focus on evaluating the efficacy and safety of novel interventions in prostate cancer.

866 active
/
2260 total (since 2008)
302
Phase 1 Active
821 total
542
Phase 2 Active
1379 total
156
Phase 3 Active
345 total
26
Phase 4 Active
77 total

Top Industry Sponsors

Sorted by active Active Done Failed
Novartis 23 11 4
AstraZeneca 18 12 2
Jiangsu HengRui Medicine Co., Ltd. 11 6 3
Pfizer 8 13 1
Bayer 7 10 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06136650 RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme LLC n=1,314
NCT07241416 RECRUITING
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=206
NCT02489318 ACTIVE NOT RECRUITING
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Aragon Pharmaceuticals, Inc. n=1,052
NCT07213674 RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen n=750
NCT06629779 RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer n=900

+ 340 more Phase 3 trials — see full database below

Prostate Cancer — Trials Started by Year (last 10 years)

2016
105
2017
116
2018
137
2019
126
2020
134
2021
150
2022
92
2023
138
2024
186
2025
159
2026
121

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Novartis
38
AstraZeneca
32
Jiangsu HengRui Medicine Co., Ltd.
20
Pfizer
22
Bayer
17
Amgen
17
Merck
15
Eli Lilly
11
Johnson & Johnson
11
Astellas Pharma Global Development, Inc.
11

Active Trials by Phase

Phase 1
302
Phase 2
542
Phase 3
156
Phase 4
26

Enrollment Size Distribution

1-50
1,085
51-200
728
201-500
207
501-1k
76
1k+
63

All Industry Sponsors

Sorted by active Active Done Failed
Novartis 23 11 4
AstraZeneca 18 12 2
Jiangsu HengRui Medicine Co., Ltd. 11 6 3
Pfizer 8 13 1
Bayer 7 10 0
Amgen 7 7 3
Merck 4 9 2
Eli Lilly 4 7 0
Johnson & Johnson 4 7 0
Astellas Pharma Global Development, Inc. 4 5 2
Exelixis 4 2 3
Regeneron 4 0 1
Roche 3 5 0
Telix Pharmaceuticals (Innovations) Pty Limited 3 2 0
Daiichi Sankyo 3 0 1
NCT07574489 NOT YET RECRUITING
Whole Versus Partial Gland Boost During Prostate SBRT
University of Nebraska n=186
NCT06136650 RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme LLC n=1,314
NCT07241416 RECRUITING
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=206
NCT02489318 ACTIVE NOT RECRUITING
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Aragon Pharmaceuticals, Inc. n=1,052
NCT07213674 RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen n=750
NCT06629779 RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer n=900
NCT04497844 ACTIVE NOT RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Janssen Research & Development, LLC n=696
NCT06931340 RECRUITING
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology n=1,260
NCT06925737 RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme LLC n=1,440
NCT07548164 RECRUITING
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center n=224
NCT01368588 ACTIVE NOT RECRUITING
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group n=2,590
NCT05946213 RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology n=1,209
NCT02319837 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer n=1,068
NCT04134260 RECRUITING
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology n=586
NCT03819101 RECRUITING
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=1,210
NCT06056830 RECRUITING
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Clarity Pharmaceuticals Ltd n=383
NCT06764485 RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Celgene n=960
NCT04136353 ACTIVE NOT RECRUITING
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
University of Sydney n=1,100
NCT06136624 RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Merck Sharp & Dohme LLC n=1,310
NCT07028853 RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer n=1,000
NCT04423211 RECRUITING
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group n=804
NCT06520345 RECRUITING
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited n=520
NCT07365995 RECRUITING
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE n=736
NCT04493853 ACTIVE NOT RECRUITING
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
AstraZeneca n=1,012
NCT06551324 ACTIVE NOT RECRUITING
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer n=600
NCT05050084 ACTIVE NOT RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology n=2,050
NCT04513717 ACTIVE NOT RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology n=2,753
NCT06780670 RECRUITING
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Novartis Pharmaceuticals n=443
NCT05939414 RECRUITING
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Novartis Pharmaceuticals n=450
NCT04916613 RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER n=300
NCT03706365 ACTIVE NOT RECRUITING
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Eli Lilly and Company n=393
NCT06274047 RECRUITING
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center n=120
NCT06952803 RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
AstraZeneca n=700
NCT05794906 ACTIVE NOT RECRUITING
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Bayer n=985
NCT04076059 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Astellas Pharma China, Inc. n=180
NCT06439225 RECRUITING
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Canadian Cancer Trials Group n=236
NCT06592924 RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Canadian Cancer Trials Group n=830
NCT06235697 RECRUITING
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Canadian Cancer Trials Group n=710
NCT06122584 RECRUITING
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH n=380
NCT06970847 ACTIVE NOT RECRUITING
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Clarity Pharmaceuticals Ltd n=220
NCT04787744 RECRUITING
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development n=464
NCT06235151 RECRUITING
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Curium US LLC n=439
NCT04821622 ACTIVE NOT RECRUITING
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer n=599
NCT06626022 RECRUITING
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
University of Alberta n=1,284
NCT06120491 RECRUITING
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
AstraZeneca n=1,800
NCT02064673 RECRUITING
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
yair lotan n=650
NCT07500701 RECRUITING
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
Samsung Medical Center n=270
NCT05678322 ACTIVE NOT RECRUITING
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NYU Langone Health n=26
NCT07426055 RECRUITING
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,200
NCT07426094 RECRUITING
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,600
NCT03594760 RECRUITING
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=1,000
NCT06282588 RECRUITING
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Cancer Research Antwerp n=493
NCT07477626 ACTIVE NOT RECRUITING
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
Sun Yat-sen University n=372
NCT05884398 ACTIVE NOT RECRUITING
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Janssen Research & Development, LLC n=420
NCT05171816 ACTIVE NOT RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca n=110
NCT06691984 ACTIVE NOT RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen n=707
NCT05154162 ACTIVE NOT RECRUITING
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
Peter MacCallum Cancer Centre, Australia n=660
NCT03495427 RECRUITING
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
H. Lee Moffitt Cancer Center and Research Institute n=60
NCT03574571 ACTIVE NOT RECRUITING
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center n=732
NCT06650579 RECRUITING
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University n=72
NCT06855277 RECRUITING
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Novartis Pharmaceuticals n=940
NCT07427043 RECRUITING
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
Brigham and Women's Hospital n=300
NCT04455750 ACTIVE NOT RECRUITING
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology n=61
NCT06563388 RECRUITING
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Roswell Park Cancer Institute n=800
NCT07311694 RECRUITING
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=370
NCT03732820 ACTIVE NOT RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca n=895
NCT06825091 RECRUITING
Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
University Health Network, Toronto n=320
NCT06470243 RECRUITING
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network n=528
NCT06205316 RECRUITING
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic n=118
NCT03367702 ACTIVE NOT RECRUITING
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NRG Oncology n=692
NCT05838716 RECRUITING
Vitamin D for Prostate Endocrine Therapy
University of Rochester n=240
NCT04647526 ACTIVE NOT RECRUITING
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company n=455
NCT07333066 NOT YET RECRUITING
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD n=320
NCT03258320 RECRUITING
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine n=300
NCT02051218 ACTIVE NOT RECRUITING
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute n=1,380
NCT07293585 RECRUITING
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Jonsson Comprehensive Cancer Center n=200
NCT04446117 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Exelixis n=575
NCT03701581 RECRUITING
4-aminopyridine Treatment for Nerve Injury
John Elfar n=70
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT07260435 RECRUITING
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
Nick Beije n=400
NCT05786716 RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK n=30
NCT03987386 ACTIVE NOT RECRUITING
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center n=186
NCT04263025 RECRUITING
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Hackensack Meridian Health n=100
NCT07209878 RECRUITING
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University n=100
NCT07200830 NOT YET RECRUITING
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology n=1,524
NCT06320067 RECRUITING
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
University College, London n=3,360
NCT05520255 RECRUITING
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
University of Alberta n=2,800
NCT02194842 ACTIVE NOT RECRUITING
Phase III Radium 223 mCRPC-PEACE III
European Organisation for Research and Treatment of Cancer - EORTC n=446
NCT05974774 RECRUITING
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
European Organisation for Research and Treatment of Cancer - EORTC n=1,600
NCT03678025 RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network n=1,273
NCT07052214 RECRUITING
PSMA PET Combined With MRI for the Detection of PCa
Telix Pharmaceuticals (Innovations) Pty Limited n=204
NCT01230866 ACTIVE NOT RECRUITING
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
Proton Collaborative Group n=150
NCT01492972 RECRUITING
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group n=192
NCT03348670 ACTIVE NOT RECRUITING
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT01407263 ACTIVE NOT RECRUITING
Trial of Modifications to Radical Prostatectomy
Memorial Sloan Kettering Cancer Center n=3,204
NCT06986083 RECRUITING
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center n=800
NCT01436968 ACTIVE NOT RECRUITING
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Candel Therapeutics, Inc. n=711
NCT01952223 ACTIVE NOT RECRUITING
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
UNICANCER n=761
NCT04181203 ACTIVE NOT RECRUITING
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
UNICANCER n=490
NCT05448547 RECRUITING
Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
Sven Löffeler n=980
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT06625970 RECRUITING
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
UNICANCER n=700
NCT04115007 ACTIVE NOT RECRUITING
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
UNICANCER n=550
NCT03531099 ACTIVE NOT RECRUITING
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
Hospices Civils de Lyon n=108
NCT03769766 RECRUITING
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
University of Texas Southwestern Medical Center n=291
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT06972511 RECRUITING
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
RenJi Hospital n=120
NCT00567580 ACTIVE NOT RECRUITING
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group n=1,792
NCT06945315 RECRUITING
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Icahn School of Medicine at Mount Sinai n=196
NCT06112990 RECRUITING
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
University of Utah n=200
NCT06922903 NOT YET RECRUITING
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
Yunhe Pharmaceutical (Tianjin) Co., Ltd n=240
NCT06922929 NOT YET RECRUITING
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Yunhe Pharmaceutical (Tianjin) Co., Ltd n=110
NCT03903835 RECRUITING
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Karolinska Institutet n=750
NCT04302454 ACTIVE NOT RECRUITING
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
University Medical Center Groningen n=280
NCT05169112 RECRUITING
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute n=72
NCT04794777 RECRUITING
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Stefan Carlsson n=450
NCT04557501 ACTIVE NOT RECRUITING
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=800
NCT02692105 ACTIVE NOT RECRUITING
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
British Columbia Cancer Agency n=60
NCT03525288 ACTIVE NOT RECRUITING
PSMA-PET Guided Radiotherapy
Centre hospitalier de l'Université de Montréal (CHUM) n=130
NCT06855589 NOT YET RECRUITING
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Charles LeMoyne Hospital n=400
NCT06565247 RECRUITING
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Region Västerbotten n=60
NCT06837896 NOT YET RECRUITING
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd. n=110
NCT05676203 ACTIVE NOT RECRUITING
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
Jena University Hospital n=250
NCT05381103 RECRUITING
PSMA-PET to Guide Prostatectomy
Five Eleven Pharma, Inc. n=288
NCT05348577 ACTIVE NOT RECRUITING
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
AstraZeneca n=1,035
NCT06768255 NOT YET RECRUITING
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Ding-Wei Ye n=400
NCT06754085 RECRUITING
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd. n=131
NCT04691804 ACTIVE NOT RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=496
NCT06496581 RECRUITING
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER n=500
NCT02303327 ACTIVE NOT RECRUITING
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Sir Mortimer B. Davis - Jewish General Hospital n=307
NCT01444820 ACTIVE NOT RECRUITING
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate
Sir Mortimer B. Davis - Jewish General Hospital n=329
NCT02685397 ACTIVE NOT RECRUITING
Management of Castration-Resistant Prostate Cancer with Oligometastases
Sir Mortimer B. Davis - Jewish General Hospital n=102
NCT01957436 ACTIVE NOT RECRUITING
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
UNICANCER n=1,173
NCT02799706 ACTIVE NOT RECRUITING
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC n=885
NCT05613023 RECRUITING
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Institute of Cancer Research, United Kingdom n=1,128
NCT06585007 RECRUITING
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=246
NCT06490328 RECRUITING
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Dongkook Pharmaceutical Co., Ltd. n=154
NCT05352178 RECRUITING
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=873
NCT05847348 RECRUITING
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited n=110
NCT05799248 RECRUITING
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
MidLantic Urology n=113
NCT05622162 ACTIVE NOT RECRUITING
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
ITEL Telecomunicazioni Srl n=106
NCT06350825 RECRUITING
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
The First Affiliated Hospital with Nanjing Medical University n=200
NCT05116475 RECRUITING
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=152
NCT04642027 RECRUITING
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
University Medical Center Groningen n=538
NCT01584258 ACTIVE NOT RECRUITING
Prostate Advances in Comparative Evidence
Royal Marsden NHS Foundation Trust n=2,205
NCT06177015 RECRUITING
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
The First Affiliated Hospital with Nanjing Medical University n=200
NCT04242017 RECRUITING
Long-term Better Than Short-term ADT With Salvage RT
Universitaire Ziekenhuizen KU Leuven n=394
NCT03459820 ENROLLING BY INVITATION
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
Sir Mortimer B. Davis - Jewish General Hospital n=1,500
NCT05781217 RECRUITING
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic n=534
NCT05983783 RECRUITING
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University n=200
NCT05956639 RECRUITING
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
The First Affiliated Hospital with Nanjing Medical University n=100
NCT04654338 RECRUITING
2 Ablative RadioTherapy Treatments for Prostate Cancer
Sunnybrook Health Sciences Centre n=30
NCT05019846 RECRUITING
SRT Versus SRT+ADT in Prostate Cancer
Marco Lorenzo Bonu n=310
NCT05232578 NOT YET RECRUITING
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
General University Hospital, Prague n=380
NCT07598032 NOT YET RECRUITING
Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression
University of Ilorin Teaching Hospital n=200
NCT07591467 NOT YET RECRUITING
Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=330
NCT03070886 COMPLETED
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology n=612
NCT04191096 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Merck Sharp & Dohme LLC n=1,251
NCT04261777 TERMINATED
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V. n=172
NCT05009290 TERMINATED
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Jiangsu HengRui Medicine Co., Ltd. n=391
NCT02044354 COMPLETED
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=195
NCT03274687 COMPLETED
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology n=296
NCT01546987 COMPLETED
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group n=239
NCT00936390 COMPLETED
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group n=1,538
NCT05597878 SUSPENDED
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Wake Forest University Health Sciences n=100
NCT00699751 COMPLETED
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Bayer n=921
NCT04876651 TERMINATED
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Ltd n=16
NCT06235099 COMPLETED
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Curium US LLC n=235
NCT07413120 COMPLETED
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital n=40
NCT02003924 COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Pfizer n=1,401
NCT01809691 COMPLETED
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
SWOG Cancer Research Network n=1,313
NCT03009981 COMPLETED
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC. n=504
NCT02799602 COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Bayer n=1,306
NCT02294461 COMPLETED
An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Astellas Pharma Inc n=395
NCT02677896 COMPLETED
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Astellas Pharma Global Development, Inc. n=1,150
NCT04838613 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 in BCR
Novartis Pharmaceuticals n=190
NCT04838626 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
Novartis Pharmaceuticals n=195
NCT04934722 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
Merck Sharp & Dohme LLC n=186
NCT04186845 COMPLETED
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics n=391
NCT05590793 COMPLETED
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen n=195
NCT05605964 COMPLETED
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. n=387
NCT05137561 COMPLETED
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)
Post Graduate Institute of Medical Education and Research, Chandigarh n=217
NCT05458856 COMPLETED
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
Ipsen n=147
NCT02975934 COMPLETED
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
pharmaand GmbH n=405
NCT05547386 COMPLETED
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic n=163
NCT04742361 COMPLETED
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
ABX advanced biochemical compounds GmbH n=136
NCT04100018 COMPLETED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Bristol-Myers Squibb n=1,030
NCT03072238 COMPLETED
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Hoffmann-La Roche n=1,101
NCT00667069 COMPLETED
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER n=424
NCT06984159 COMPLETED
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Changchun GeneScience Pharmaceutical Co., Ltd. n=137
NCT06795178 WITHDRAWN
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
Foresee Pharmaceuticals Co., Ltd.
NCT06795191 WITHDRAWN
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
Foresee Pharmaceuticals Co., Ltd.
NCT03936218 COMPLETED
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
Eurofarma Laboratorios S.A. n=94
NCT01220869 COMPLETED
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
Ferring Pharmaceuticals n=110
NCT02288247 COMPLETED
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
Astellas Pharma Europe Ltd. n=688
NCT04186819 COMPLETED
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics n=356
NCT03862170 TERMINATED
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
CR-CSSS Champlain-Charles-Le Moyne n=158
NCT00887198 COMPLETED
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC n=1,088
NCT03103321 COMPLETED
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
Alliance for Clinical Trials in Oncology n=158
NCT03511664 COMPLETED
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Endocyte n=861
NCT02220829 COMPLETED
Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Sir Mortimer B. Davis - Jewish General Hospital n=148
NCT01964170 COMPLETED
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Astellas Pharma Inc n=234
NCT03031821 TERMINATED
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Canadian Urologic Oncology Group n=168
NCT03777982 TERMINATED
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute n=12
NCT01272050 COMPLETED
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
Swiss Cancer Institute n=350
NCT03056638 TERMINATED
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center n=56
NCT03850795 TERMINATED
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc. n=104
NCT03389451 COMPLETED
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=30
NCT04676334 COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
pharmaand GmbH n=34
NCT04684628 SUSPENDED
68Ga-PSMA PET/CT in Prostate Cancer
University of Saskatchewan n=500
NCT03388346 COMPLETED
68Ga PSMA in Preprostatectomy Patients
Michael Graham PhD, MD n=22
NCT04644822 COMPLETED
Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.
Centre for Probe Development and Commercialization n=100
NCT04844749 TERMINATED
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Veru Inc. n=105
NCT04887506 COMPLETED
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics n=107
NCT04409288 TERMINATED
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong n=74
NCT03001869 COMPLETED
68Ga-PSMA PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital n=540
NCT05197257 COMPLETED
68Ga-PSMA-11 PET in Patients With Prostate Cancer
University of Colorado, Denver n=39
NCT00942331 COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI) n=506
NCT02987543 COMPLETED
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca n=387
NCT03761225 COMPLETED
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
AB Science n=714
NCT05771896 WITHDRAWN
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
GenesisCare USA
NCT05098327 WITHDRAWN
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
NCT00651326 TERMINATED
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
NCIC Clinical Trials Group n=48
NCT01666808 COMPLETED
FACBC Outcomes for Post Prostatectomy
Emory University n=165
NCT04914195 COMPLETED
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Bharat Serums and Vaccines Limited n=155
NCT00664456 COMPLETED
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=421
NCT05363644 WITHDRAWN
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
AdventHealth
NCT02015871 COMPLETED
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
Ferring Pharmaceuticals n=206
NCT02659527 COMPLETED
PET/MRI in Patients With Suspected Prostate Cancer
Medical University of Vienna n=220
NCT01907009 TERMINATED
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
Barts & The London NHS Trust n=29
NCT02624518 COMPLETED
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Andrei Iagaru n=122
NCT03103152 COMPLETED
A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
Queen Mary University of London n=104
NCT01238172 COMPLETED
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Alliance for Clinical Trials in Oncology n=478
NCT02438007 TERMINATED
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
LTN PHARMACEUTICALS, INC. n=953
NCT03921996 TERMINATED
Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
Swiss Cancer Institute n=57
NCT05744115 TERMINATED
Ga-68-PSMA-11 in Men With Prostate Cancer
Timothy Hoffman n=38
NCT04627896 COMPLETED
Targeted Microwave Focal Therapy
A.O.U. Città della Salute e della Scienza n=11
NCT04854993 COMPLETED
Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=34
NCT04457245 TERMINATED
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
Jonsson Comprehensive Cancer Center n=54
NCT02745587 TERMINATED
Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.
University Hospital, Ghent n=69
NCT04237584 TERMINATED
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
MANA RBM n=23
NCT02663908 TERMINATED
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Ferring Pharmaceuticals n=545
NCT02200614 COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Bayer n=1,509
NCT02961257 COMPLETED
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=196
NCT01517802 COMPLETED
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Janssen Research & Development, LLC n=32
NCT03295565 COMPLETED
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
The Netherlands Cancer Institute n=100
NCT02678351 COMPLETED
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Andrei Iagaru n=74
NCT03085095 COMPLETED
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Myovant Sciences GmbH n=1,134
NCT02673151 COMPLETED
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Andrei Iagaru n=61
NCT03800784 WITHDRAWN
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03353740 COMPLETED
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Thomas Hope n=346
NCT04563936 COMPLETED
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd. n=290
NCT03803475 COMPLETED
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
Thomas Hope n=485
NCT02981368 COMPLETED
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Progenics Pharmaceuticals, Inc. n=385
NCT02940262 COMPLETED
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Jonsson Comprehensive Cancer Center n=1,138
NCT04102553 COMPLETED
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
ABX advanced biochemical compounds GmbH n=200
NCT03739684 COMPLETED
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Progenics Pharmaceuticals, Inc. n=208
NCT03532308 TERMINATED
Nutrition and Prostate Cancer
Yale University n=19
NCT02834416 COMPLETED
ADT Exercise Trial and Economic Analysis
University Health Network, Toronto n=38
NCT02111577 COMPLETED
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
SOTIO a.s. n=1,182
NCT01538628 COMPLETED
SpaceOAR System Pivotal Study
Boston Scientific Corporation n=222
NCT03404648 COMPLETED
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
Mayo Clinic n=19
NCT03911310 COMPLETED
[18F]PSMA-11 PET/CT Phase 3 Clinical Study
University Hospital, Ghent n=96
NCT02919111 COMPLETED
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
University of California, San Francisco n=299
NCT04225299 WITHDRAWN
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
NCT03488810 WITHDRAWN
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02887976 COMPLETED
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
GU Research Network, LLC n=2
NCT01168479 COMPLETED
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
UMC Utrecht n=571
NCT01212991 COMPLETED
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Pfizer n=1,717
NCT01591122 COMPLETED
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC n=313
NCT02260817 COMPLETED
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Global Isotopes, LLC d/b/a Zevacor Molecular n=109
NCT01902823 TERMINATED
Effect of Cancer Nurse Navigators on Patient Outcomes
University of Wisconsin, Madison n=16
NCT01715129 COMPLETED
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Ipsen n=126
NCT02918357 COMPLETED
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of California, San Francisco n=385
NCT01313273 TERMINATED
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Ipsen n=3
NCT01419717 COMPLETED
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Amgen n=129
NCT01322490 COMPLETED
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Bavarian Nordic n=1,297
NCT04056754 COMPLETED
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=268
NCT01310894 COMPLETED
Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.
Steba Biotech S.A. n=413
NCT01006395 COMPLETED
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Austin Health n=64
NCT02085252 COMPLETED
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda n=116
NCT01308567 COMPLETED
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sanofi n=1,168
NCT01707966 COMPLETED
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Swiss Cancer Institute n=47
NCT01930812 COMPLETED
18F-NaF PET Imaging for Bone Scintigraphy
British Columbia Cancer Agency n=286
NCT02615067 COMPLETED
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Molecular Insight Pharmaceuticals, Inc. n=531
NCT01020448 COMPLETED
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
Ipsen n=339
NCT02680041 COMPLETED
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Blue Earth Diagnostics n=221
NCT01193257 COMPLETED
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
Millennium Pharmaceuticals, Inc. n=1,099
NCT00974311 COMPLETED
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
Pfizer n=1,199
NCT02551341 COMPLETED
Lung Protective Ventilation During Robotic Assisted Prostatectomy
Jørgen Bjerggaard Jensen n=24
NCT00838201 COMPLETED
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen n=384
NCT02840552 COMPLETED
The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital n=60
NCT02053311 WITHDRAWN
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Swiss Cancer Institute
NCT01522443 TERMINATED
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Exelixis n=119
NCT00988208 COMPLETED
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
Celgene n=1,059
NCT01605227 COMPLETED
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Exelixis n=1,028
NCT00931528 COMPLETED
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Radiation Therapy Oncology Group n=242
NCT01105338 COMPLETED
Lycopene or Green Tea for Men at Risk of Prostate Cancer
University of Bristol n=126
NCT01613651 COMPLETED
Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer
City of Hope Medical Center n=191
NCT02526784 COMPLETED
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals n=120
NCT00925600 COMPLETED
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Amgen n=769
NCT01193244 COMPLETED
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Millennium Pharmaceuticals, Inc. n=1,560
NCT01308580 COMPLETED
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sanofi n=1,200
NCT01415960 COMPLETED
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
GP-Pharm n=163
NCT00928434 COMPLETED
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals n=409
NCT01188187 COMPLETED
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Achieve Life Sciences n=1,022
NCT01578655 COMPLETED
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Achieve Life Sciences n=630
NCT01083615 TERMINATED
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences n=14
NCT00861614 COMPLETED
Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb n=988
NCT01057810 COMPLETED
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb n=837
NCT00691899 WITHDRAWN
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
Merck Sharp & Dohme LLC
NCT01981707 TERMINATED
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
University Hospital, Grenoble n=12
NCT01875393 COMPLETED
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
Steba Biotech S.A. n=81
NCT01603420 TERMINATED
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group n=2
NCT01234311 COMPLETED
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Active Biotech AB n=1,245
NCT00685646 COMPLETED
Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=227
NCT01656161 COMPLETED
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA n=120
NCT01546623 COMPLETED
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Takeda n=160
NCT00809458 TERMINATED
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
New Mexico Cancer Research Alliance n=15
NCT01744366 COMPLETED
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
Ferring Pharmaceuticals n=285
NCT01242748 TERMINATED
A Degarelix Trial in Patients With Prostate Cancer
Ferring Pharmaceuticals n=288
NCT01824342 COMPLETED
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Amgen n=18
NCT01254279 COMPLETED
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi n=984
NCT02257827 COMPLETED
Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule
Gustavo Viani Arruda n=220
NCT00801242 COMPLETED
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals n=220
NCT00949962 TERMINATED
Post-operative or Early Salvage XRT and ADT for High Risk PCa
European Organisation for Research and Treatment of Cancer - EORTC n=87
NCT00946920 COMPLETED
A Trial of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals n=859
NCT00950911 COMPLETED
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen n=35
NCT01715064 COMPLETED
Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients
University of Guelph-Humber n=36
NCT00922129 WITHDRAWN
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
St. Joseph's Healthcare Hamilton
NCT00884273 COMPLETED
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals n=182
NCT00831233 TERMINATED
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals n=42
NCT01901042 COMPLETED
Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms
Federal University of Mato Grosso n=20
NCT01215513 COMPLETED
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
Ferring Pharmaceuticals n=127
NCT01071915 COMPLETED
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
Ferring Pharmaceuticals n=157
NCT01174017 COMPLETED
Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate
British Columbia Cancer Agency n=41
NCT00967018 COMPLETED
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals n=77
NCT00658229 COMPLETED
The Physical Exercise and Prostate Cancer Study
Oslo University Hospital n=60
NCT00833248 COMPLETED
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals n=246
NCT00617669 COMPLETED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
AstraZeneca n=1,494
NCT00626548 TERMINATED
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
AstraZeneca n=2,577
NCT00911027 TERMINATED
SonoVue Guided Prostate Biopsy
Bracco Diagnostics, Inc n=282
NCT01367418 COMPLETED
Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy
Örebro University, Sweden n=26
NCT00626431 COMPLETED
A Study of Leuprolide to Treat Prostate Cancer
Abbott n=310
NCT00630799 TERMINATED
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
GP-Pharm n=20

Full Prostate Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only